Avalo Therapeutics (AVTX) EBIT Margin (2016 - 2025)
Avalo Therapeutics posted quarterly EBIT Margin of 33461.02% for Q4 2025, down 2652820.0% year-on-year from N/an in Q4 2024, and down 382.65% on a QoQ basis from 6932.81% in Q4 2024.
Avalo Therapeutics (AVTX) has 10 years of EBIT Margin data on file, last reported at 33461.02% in Q4 2025.
- For the quarter ending Q4 2025, EBIT Margin fell 2652820.0% year-over-year to 33461.02%; the trailing twelve-month figure through Dec 2025 stood at 14585.0% (up 95105.0% YoY), and the FY2025 full-year result was 123601.69%, down 10806609.0% from the prior year.
- EBIT Margin for Q4 2025 stood at 33461.02%, down from 6932.81% in the prior quarter.
- Across five years, EBIT Margin topped out at 27.39% in Q3 2022 and bottomed at 33461.02% in Q4 2025.
- The 5-year median for EBIT Margin is 1588.98% (2023), against an average of 4782.2%.
- The widest annual swing landed in 2022, when EBIT Margin jumped 721400 bps; it then plunged 2652820 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 8202.28% in 2021, then jumped by 88 bps to 988.28% in 2022, then slumped by 36 bps to 1341.16% in 2023, then sank by 417 bps to 6932.81% in 2024, then plunged by 383 bps to 33461.02% in 2025.
- The last three EBIT Margin figures came in at 33461.02% (Q4 2025), 6932.81% (Q4 2024), and 5165.06% (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -33,461.02% |
| Dec 31, 2024 | -6,932.81% |
| Sep 30, 2024 | -5,165.06% |
| Dec 31, 2023 | -1,341.16% |
| Sep 30, 2023 | -1,588.98% |
| Jun 30, 2023 | -1,111.98% |
| Mar 31, 2023 | -1,850.95% |
| Dec 31, 2022 | -988.28% |
| Sep 30, 2022 | 27.39% |
| Jun 30, 2022 | -1,145.01% |
| Mar 31, 2022 | -1,777.75% |
| Dec 31, 2021 | -8,202.28% |
| Sep 30, 2021 | -1,219.48% |
| Jun 30, 2021 | -510.55% |
| Mar 31, 2021 | -6,465.12% |
| Dec 31, 2020 | -1,091.45% |
| Sep 30, 2020 | -1,195.05% |
| Jun 30, 2020 | -883.03% |
| Mar 31, 2020 | -1,140.63% |
| Dec 31, 2019 | -985.32% |
| Sep 30, 2019 | -130.00% |
| Jun 30, 2019 | -183.06% |
| Mar 31, 2019 | -194.26% |
| Dec 31, 2018 | 24.67% |
| Sep 30, 2018 | -596.68% |
| Jun 30, 2018 | -120.22% |
| Mar 31, 2018 | -83.75% |
| Dec 31, 2017 | -228.00% |
| Sep 30, 2017 | 87.55% |
| Jun 30, 2017 | -1,124.84% |
| Mar 31, 2017 | -494.30% |
| Dec 31, 2016 | -926.56% |
| Sep 30, 2016 | -1,854.85% |
| Jun 30, 2016 | -536.22% |